ABL, S.A. and Evivar Medical Pty Ltd today announced the completion of agreements to cross-licence their respective intellectual property portfolios and to form strategic alliances based on the use of their proprietary disease management platforms in HIV and Hepatitis (namely TherapyEdge, ViroScore and SeqHepB).The agreements will include joint strategies in development and commercialisation of their products, and joint research efforts to develop new products.
Advanced Biological Laboratories S.A (ABL) and Evivar Medical Pty Ltd (Evivar) today announced the completion of agreements to cross-licence their respective intellectual property portfolios, and to form strategic alliances based on the use of their proprietary disease management platforms in HIV and Hepatitis B.
TherapyEdge is a comprehensive patient record hospital information system to be used for data and patient management, monitoring and reporting applications. It is already integrating decision support and expert systems for HIV or TB disease management, allowing personalized therapy selection and optimal diagnostic monitoring and evaluation. Through HL7, TherapyEdge has already interfaced with Laboratory and Hospital Information Systems in Europe, Asia, Africa and soon in the USA. It can also be combined with the ViroScore Suite sequence database and drug resistance (HIV and TB) interpretation systems to create a powerful global clinical and research patient management system. It is used in over 75 hospitals and clinical settings in 35 countries as their primary longitudinal patient record and research tool, by government organizations to track program indicators and expenditures, by researchers to learn more about the resistance profiles and by virologists and clinicians to improve the quality of care.